
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Hldgs is a commercial-stage pharmaceutical company with a promising outlook due to their sole source of revenue, Wakix, experiencing strong underlying demand and potential for franchise expansion in CNS indications. Positive legal decisions for Wakix patents and successful clinical development of clemizole hydrochloride in Dravet or Lennox-Gastaut syndromes could provide additional upside to their current outlook. Risks include potential competition in the sodium oxybate market, slower growth in patient adds, unsuccessful clinical trials, and competition from generic pitolisant. With limited cash reserves, the success of future growth drivers and pipeline assets will be crucial for sustaining positive cash flows.
Bears say
Harmony Biosciences Hldgs is facing potential risks, such as safety concerns and regulatory outcomes, that could negatively impact its future financial performance. Additionally, its pipeline drugs have longer half-lives than its competitors, potentially making it less attractive for daily dosing. Its focus on assets with revenue potential in the 2028-2032 timeline suggests a lack of near-term profitability, and its reliance on drug repurposing and potential recruitment difficulties highlight potential challenges in product development.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares